What are the adverse reactions of Ivonescimab injection?

Ivonescimab injection (Ivonescimab) has been approved for use in combination with pemetrexed (pemetrexed) and carboplatin (carboplatin). It is mainly used to treat epidermal growth factor receptors. Patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with EGFR (EGFR) mutations, especially those with disease progression after treatment with tyrosine kinase inhibitors (TKIs). However, in its clinical application, adverse reactions are an important aspect to pay attention to.

According to clinical studies of ivocilimab, adverse reactions include but are not limited to the following: rash, loss of appetite, epistaxis, fatigue, infusion-related reactions, constipation and anemia, etc. In addition, cardiac arrhythmia and increased blood pressure are also adverse reactions worthy of attention. Abnormalities in thyroid function are also evident, including hypothyroidism and hyperthyroidism, and symptoms such as weight loss, urinary tract infections, itching, and mouth ulcers are also frequently reported.

In some relatively severe cases, patients may develop interstitial lung disease, gum bleeding, hemoptysis, upper respiratory tract infection, mucosal inflammation, etc. In particular, cardiopulmonary system symptoms such as cough and supraventricular arrhythmia also require attention. These adverse reactions not only affect patients' quality of life, but also require timely monitoring and intervention by doctors.

In addition, common abnormalities in laboratory tests also require attention, including decreased leukocytes, decreased neutrophils, increased aspartate aminotransferase, decreased platelets, and proteinuria. Changes in these laboratory indicators may indicate changes in the patient's immune status and liver and kidney function. Others, such as elevated amylase, elevated γ-glutamyl transferase, hypercholesterolemia, hypertriglyceridemia, hypoalbuminemia, elevated blood uric acid, decreased lymphocytes, elevated blood glucose, hyperlipidemia, and increased markers of myocardial necrosis, require comprehensive evaluation in clinical management.

Reference materials:https://www.akesobio.com/en/media/akeso-news/240908/